ELVN
Enliven Therapeutics Inc.
NASDAQ: ELVN · HEALTHCARE · BIOTECHNOLOGY
$42.40
-1.35% today
Updated 2026-04-29
Market cap
$2.58B
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-1.83
Dividend yield
—
52W range
$15 – $49
Volume
1.2M
Enliven Therapeutics Inc. (ELVN) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | $33000.00 | $97000.00 | $99000.00 | $622000.00 | $297000.00 | $317000.00 | $263000.00 |
| Gross profit | — | — | $-33000.00 | $-97000.00 | $-99000.00 | $-622000.00 | $-297000.00 | $-317000.00 | $-263000.00 |
| Gross margin | — | — | — | — | — | — | — | — | — |
| R&D | $7.92M | $8.24M | $19.01M | $8.24M | $20.47M | $31.02M | $64.57M | $80.78M | $85.86M |
| SG&A | — | $2.44M | $5.11M | $1.08M | $4.29M | $7.77M | $18.95M | $23.78M | $33.80M |
| Operating income | $-8.90M | $-10.68M | $-24.12M | $-9.32M | $-24.76M | $-38.79M | $-83.53M | $-104.55M | $-119.66M |
| Operating margin | — | — | — | — | — | — | — | — | — |
| EBITDA | $221000.00 | $-11.34M | $-23.43M | $-9.27M | $-24.65M | $-38.58M | $-83.23M | $-104.24M | $-119.39M |
| EBITDA margin | — | — | — | — | — | — | — | — | — |
| EBIT | — | $-10.68M | $-23.46M | $-9.32M | $-24.76M | $-38.79M | $-83.53M | $-104.55M | $-119.66M |
| Interest expense | — | — | — | — | $93000.00 | $1.22M | — | — | — |
| Income tax | — | — | — | — | — | — | — | — | — |
| Effective tax rate | — | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | — | $-11.34M | $-23.46M | $-18.97M | $-24.74M | $-37.66M | $-71.58M | $-89.02M | $-103.69M |
| Net income growth (YoY) | — | — | -107.0% | +19.2% | -30.4% | -52.2% | -90.1% | -24.4% | -16.5% |
| Profit margin | — | — | — | — | — | — | — | — | — |